Page 263 - SAHCS HIVMed Journal Vol 20 No 1 2019

Page 7 of 8 Original Research

24
SJS/TEN. There was no statistically significant difference Data availability statement
between CD4 cell count and SCORTEN score between the Data sharing is not applicable to this article as no new data
pregnant and the non-pregnant women. Thus, the severity were created or analysed in this study.
of immunosuppression and severity of the drug reaction and
predicted mortality was not influenced by pregnancy.
Disclaimer
SCORTEN score directly correlated to the severity of the The views and opinions expressed in this article are those of
drug reaction. There was no significant correlation between the authors and do not necessarily reflect the official policy or
the CD4 cell count and SCORTEN score, the severity of the position of any affiliated agency of the authors.
drug reaction and the various complications. This could be
explained by the fact that CD8 cytotoxic T cells are the main References
cells resulting in keratinocyte apoptosis. 13,53 Yang et al. noted
that HIV infection depleted the CD4+ regulatory cells 1. Wolf R, Davidovici B. Severe cutaneous adverse drug reactions: Who should treat,
(CD4+CD25+), and this resulted in the unregulated activity where and how?: Facts and controversies. Clin Dermatol. 2010;28(3):344–348.
https://doi.org/10.1016/j.clindermatol.2009.06.020
of the CD8 cytotoxic T cells which resulted in TEN. 54 2. Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: Part I.
Introduction, history, classification, clinical features, systemic manifestations,
etiology, and immunopathogenesis. J Am Acad Dermatol. 2013;69(2):173.e1–173.
Marks et al. noted that drug reactions to anti-tuberculosis e13. https://doi.org/10.1016/j.jaad.2013.05.003
therapy occurred in 13.0% of the non-HIV-infected patients 3. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical
and 27.0% of the HIV-infected patients. Patients with classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome,
55
and erythema multiforme. Arch Dermatol. 1993;129(1):92–96. https://doi.org/
SJS/TEN are often co-infected with tuberculosis, which further 10.1001/archderm.1993.01680220104023
increases the mortality rate. Ten of the patients in our study 4. Yang Y, Xu J, Li F, Zhu X. Combination therapy of intravenous immunoglobulin and
9
corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson
group (27.8%) reacted to anti-tuberculosis treatment, and this syndrome: A retrospective comparative study in China. Int J Dermatol. 2009
was very similar to Marks et al.’s findings. Co-infection with Oct;48(10):1122–1128. https://doi.org/10.1111/j.1365-4632.2009.04166.x
TB was not associated with mortality in our cohort. 5. Moran NF. Maternal deaths due to adverse drug reactions to nevirapine containing
HAART: New recommendations for ARV therapy in pregnancy in South Africa.
Obstetrics Gynaecol Forum. 2012;22(2):29–32.
The limitations of this study are the retrospective study design 6. Tan SK, Tay YK. Profile and pattern of Stevens-Johnson syndrome and toxic
epidermal necrolysis in a general hospital in Singapore: Treatment outcomes. Acta
and the small sample of patients. Future recommendations Derm Venereol. 2012 Jan;92(1):62–66. https://doi.org/10.2340/00015555-1169
would be for larger randomised controlled studies to confirm 7. Wolkenstein P, Carriere V, Charue D, et al. A slow acetylator genotype is a risk
the role of short course systemic corticosteroids in the factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson
syndrome. Pharmacogenetics. 1995 Aug;5(4):255–258. https://doi.org/10.1097/
management of HIV-associated SJS/TENS. 00008571-199508000-00011
8. Dietrich A, Kawakubo Y, Rzany B, Mockenhaupt M, Simon JC, Schopf E. Low
N-acetylating capacity in patients with Stevens-Johnson syndrome and toxic
Conclusion epidermal necrolysis. Exp Dermatol. 1995 Oct;4(5):313–316. https://doi.org/
10.1111/j.1600-0625.1995.tb00211.x
This retrospective study has shown that an intensive skin 9. Kannenberg SM, Jordaan HF, Koegelenberg CF, Von Groote-Bidlingmaier F, Visser
WI. Toxic epidermal necrolysis and Stevens-Johnson syndrome in South Africa:
care regimen in combination with systemic corticosteroids A 3-year prospective study. QJM. 2012 Sep;105(9):839–846. https://doi.org/
10. 1093/qjmed/hcs078
and/or IVIG in HIV-infected SJS and TEN patients, 10. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P.
respectively, treated in a tertiary dermatology ward resulted SCORTEN: A severity-of-illness score for toxic epidermal necrolysis. J Investig
in a 97.2% survival rate. Short course (3 days) systemic Dermatol. 2000 Aug;115(2):149–153. https://doi.org/10.1046/j.1523-1747.2000.
00061.x
steroids were not associated with significant mortality in 11. Abood GJ, Nickoloff BJ, Gamelli RL. Treatment strategies in toxic epidermal
this HIV-infected cohort. A randomised controlled study is necrolysis syndrome: Where are we at? J Burn Care Res. 2008;29(1):269–276.
https://doi.org/10.1097/BCR.0b013e31815f3658
needed to confirm the results of this study.
12. Kardaun SH, Jonkman MF. Dexamethasone pulse therapy for Stevens-Johnson
syndrome/toxic epidermal necrolysis. Acta Derm Venereol. 2007;87(2):144–148.
https://doi.org/10.2340/00015555-0214
Acknowledgement 13. Chave TA, Mortimer NJ, Sladden MJ, Hall AP, Hutchinson PE. Toxic epidermal
necrolysis: Current evidence, practical management and future directions. Br J
Sincere appreciation to Ms P. Jika in preparation of this Dermatol. 2005 Aug;153(2):241–253. https://doi.org/10.1111/j.1365-2133.2005.
manuscript and to Dr Peer for reviewing the manuscript. 06721.x
14. French LE, Trent JT, Kerdel FA. Use of intravenous immunoglobulin in toxic
epidermal necrolysis and Stevens–Johnson syndrome: Our current understanding.
Competing interest Int Immunopharmacol. 2006;6(4):543–549. https://doi.org/10.1016/j.intimp.
2005.11.012
The authors have declared that no competing interests exist. 15. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade
of CD95 with human intravenous immunoglobulin. Science (New York, NY). 1998
Oct 16;282(5388):490–493. https://doi.org/10.1126/science.282.5388.490
Author contributions 16. Prins C, Kerdel FA, Padilla RS, et al. Treatment of toxic epidermal necrolysis
with high-dose intravenous immunoglobulins: Multicenter retrospective analysis
of 48 consecutive cases. Arch Dermatol. 2003 Jan;139(1):26–32. https://doi.org/
A.V.C., N.C.D., H.D and C.A. equally contributed to the 10.1001/archderm.139.1.26
writing and research is this article. 17. Widgerow AD. Toxic epidermal necrolysis – Management issues and treatment
options. Int J Burns Trauma. 2011;1(1):42–50.
18. Criton S, Devi K, Sridevi PK, Asokan PU. Toxic epidermal necrolysis – A retrospective
Funding study. Int J Dermatol. 1997 Dec;36(12):923–925. https://doi.org/10.1046/ j.1365-
4362.1997.00100.x
This research received no specific grant from any funding 19. Wolf R, Ruocco V, Jablonska S. Treatment of toxic epidermal necrolysis syndrome
with ‘disease-modifying’ drugs: The controversy goes on. Clin Dermatol.
agency in the public, commercial, or not-for-profit sectors. 2004;22(3): 267–269. https://doi.org/10.1016/j.clindermatol.2004.03.016

http://www.sajhivmed.org.za 256 Open Access